Parkinson's disease home diary: Further validation and implications for clinical trials
Identifieur interne : 003C29 ( Main/Exploration ); précédent : 003C28; suivant : 003C30Parkinson's disease home diary: Further validation and implications for clinical trials
Auteurs : Robert A. Hauser [États-Unis] ; Frieda Deckers [Belgique] ; Philippe Lehert [Belgique]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Clinical Trials as Topic (standards), Clinical trial, Dyskinesias (epidemiology), Feasibility Studies, Humans, Medical Records, Middle Aged, Nervous system diseases, Parkinson Disease (diagnosis), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Predictive Value of Tests, Reproducibility of Results, Severity of Illness Index, Validation, clinical trials, diary, dyskinesia, motor fluctuations, troublesome dyskinesia, validation.
- MESH :
- diagnosis : Parkinson Disease.
- epidemiology : Dyskinesias, Parkinson Disease.
- physiopathology : Parkinson Disease.
- standards : Clinical Trials as Topic.
- Adult, Aged, Aged, 80 and over, Feasibility Studies, Humans, Medical Records, Middle Aged, Predictive Value of Tests, Reproducibility of Results, Severity of Illness Index.
Abstract
We provide further validation of a Parkinson's disease (PD) home diary and explore implications for practical use in clinical trials. We previously developed and published a home PD diary that includes the categories ASLEEP, off, on without dyskinesia, on with nontroublesome dyskinesia, and on with troublesome dyskinesia [Hauser et al., J Clin Neuropharmacol 2000;23:75–81] and demonstrated that patients generally consider off time and on time with troublesome dyskinesia “bad time” and on time without dyskinesia or with nontroublesome dyskinesia “good time”. We suggested that that on time without dyskinesia or with nontroublesome dyskinesia would be an appropriate outcome measure in clinical trials of advanced PD patients. In the current study, PD patients with motor fluctuations and dyskinesia (present more than 25% of the awake day and at least moderately disabling) completed daily diaries on 3 consecutive days in each of 2 consecutive weeks. In addition, patients provided responses to five questions regarding dyskinesia and their motor response through the day on visual analog scales (VAS). Three hundred two patients from 10 countries participated. Eighty‐three percent (n = 252) completed six diaries without missing or duplicate entries. Seventy‐six percent of the missing or duplicate entries occurred after Day 3. Mean percent of the awake day on without dyskinesia or with nontroublesome dyskinesia (“good on”, ONG%) was observed to be very stable over time (repeated measure analysis of variance, P = 0.99). Coefficients of reliability as calculated by Cronbach's α were as follows: 2 days, r = 0.806; 3 days, r = 0.868; 4 days, r = 0.918; 5 days, r = 0.934; 6 days, r = 0.946. The standard error of measurement (SEM) was calculated to be 10.75%. VAS responses to the question, “How much of the day today did you experience a good response?” more strongly correlated with ONG% (0.41) than ON% (0.24). The diary appears to be sufficiently simple and feasible. Test–retest reliability was good, and reliability increased with increasing number of diary days but compliance diminished beyond 3 days. Good on time (ONG = on time without dyskinesia or with nontroublesome dyskinesia) most strongly correlated with patients' perceived duration of a good response through the day and is an important outcome variable. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20248
Affiliations:
- Belgique, États-Unis
- Floride, Région de Bruxelles-Capitale
- Bruxelles, Tampa
- Université de Floride du Sud
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001323
- to stream Istex, to step Curation: 001323
- to stream Istex, to step Checkpoint: 002610
- to stream PubMed, to step Corpus: 003256
- to stream PubMed, to step Curation: 003256
- to stream PubMed, to step Checkpoint: 003380
- to stream Ncbi, to step Merge: 001032
- to stream Ncbi, to step Curation: 001032
- to stream Ncbi, to step Checkpoint: 001032
- to stream Main, to step Merge: 005587
- to stream PascalFrancis, to step Corpus: 002003
- to stream PascalFrancis, to step Curation: 000D18
- to stream PascalFrancis, to step Checkpoint: 002068
- to stream Main, to step Merge: 005906
- to stream Main, to step Curation: 003C29
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease home diary: Further validation and implications for clinical trials</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Deckers, Frieda" sort="Deckers, Frieda" uniqKey="Deckers F" first="Frieda" last="Deckers">Frieda Deckers</name>
</author>
<author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A889A4E26288514F39A3EAE262E43FAA25BB0C01</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20248</idno>
<idno type="url">https://api.istex.fr/document/A889A4E26288514F39A3EAE262E43FAA25BB0C01/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001323</idno>
<idno type="wicri:Area/Istex/Curation">001323</idno>
<idno type="wicri:Area/Istex/Checkpoint">002610</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hauser R:parkinson:s:disease</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15390057</idno>
<idno type="wicri:Area/PubMed/Corpus">003256</idno>
<idno type="wicri:Area/PubMed/Curation">003256</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003380</idno>
<idno type="wicri:Area/Ncbi/Merge">001032</idno>
<idno type="wicri:Area/Ncbi/Curation">001032</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001032</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hauser R:parkinson:s:disease</idno>
<idno type="wicri:Area/Main/Merge">005587</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0069710</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002003</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D18</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002068</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Hauser R:parkinson:s:disease</idno>
<idno type="wicri:Area/Main/Merge">005906</idno>
<idno type="wicri:Area/Main/Curation">003C29</idno>
<idno type="wicri:Area/Main/Exploration">003C29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease home diary: Further validation and implications for clinical trials</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Deckers, Frieda" sort="Deckers, Frieda" uniqKey="Deckers F" first="Frieda" last="Deckers">Frieda Deckers</name>
<affiliation wicri:level="3"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>Merck KGaA, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Statistics, University of Mons, Fucam</wicri:regionArea>
<wicri:noRegion>Fucam</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-12">2004-12</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1409">1409</biblScope>
<biblScope unit="page" to="1413">1413</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A889A4E26288514F39A3EAE262E43FAA25BB0C01</idno>
<idno type="DOI">10.1002/mds.20248</idno>
<idno type="ArticleID">MDS20248</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Clinical Trials as Topic (standards)</term>
<term>Clinical trial</term>
<term>Dyskinesias (epidemiology)</term>
<term>Feasibility Studies</term>
<term>Humans</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Predictive Value of Tests</term>
<term>Reproducibility of Results</term>
<term>Severity of Illness Index</term>
<term>Validation</term>
<term>clinical trials</term>
<term>diary</term>
<term>dyskinesia</term>
<term>motor fluctuations</term>
<term>troublesome dyskinesia</term>
<term>validation</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Feasibility Studies</term>
<term>Humans</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Reproducibility of Results</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Validation</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="fr">We provide further validation of a Parkinson's disease (PD) home diary and explore implications for practical use in clinical trials. We previously developed and published a home PD diary that includes the categories ASLEEP, off, on without dyskinesia, on with nontroublesome dyskinesia, and on with troublesome dyskinesia [Hauser et al., J Clin Neuropharmacol 2000;23:75–81] and demonstrated that patients generally consider off time and on time with troublesome dyskinesia “bad time” and on time without dyskinesia or with nontroublesome dyskinesia “good time”. We suggested that that on time without dyskinesia or with nontroublesome dyskinesia would be an appropriate outcome measure in clinical trials of advanced PD patients. In the current study, PD patients with motor fluctuations and dyskinesia (present more than 25% of the awake day and at least moderately disabling) completed daily diaries on 3 consecutive days in each of 2 consecutive weeks. In addition, patients provided responses to five questions regarding dyskinesia and their motor response through the day on visual analog scales (VAS). Three hundred two patients from 10 countries participated. Eighty‐three percent (n = 252) completed six diaries without missing or duplicate entries. Seventy‐six percent of the missing or duplicate entries occurred after Day 3. Mean percent of the awake day on without dyskinesia or with nontroublesome dyskinesia (“good on”, ONG%) was observed to be very stable over time (repeated measure analysis of variance, P = 0.99). Coefficients of reliability as calculated by Cronbach's α were as follows: 2 days, r = 0.806; 3 days, r = 0.868; 4 days, r = 0.918; 5 days, r = 0.934; 6 days, r = 0.946. The standard error of measurement (SEM) was calculated to be 10.75%. VAS responses to the question, “How much of the day today did you experience a good response?” more strongly correlated with ONG% (0.41) than ON% (0.24). The diary appears to be sufficiently simple and feasible. Test–retest reliability was good, and reliability increased with increasing number of diary days but compliance diminished beyond 3 days. Good on time (ONG = on time without dyskinesia or with nontroublesome dyskinesia) most strongly correlated with patients' perceived duration of a good response through the day and is an important outcome variable. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Région de Bruxelles-Capitale</li>
</region>
<settlement><li>Bruxelles</li>
<li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Deckers, Frieda" sort="Deckers, Frieda" uniqKey="Deckers F" first="Frieda" last="Deckers">Frieda Deckers</name>
</region>
<name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:A889A4E26288514F39A3EAE262E43FAA25BB0C01 |texte= Parkinson's disease home diary: Further validation and implications for clinical trials }}
This area was generated with Dilib version V0.6.23. |